ATAI Life Sciences NV
NASDAQ:ATAI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
DE |
|
Kingsoft Cloud Holdings Ltd
NASDAQ:KC
|
CN |
|
C
|
Changshu Guorui Technology Co Ltd
SZSE:300600
|
CN |
|
Tongtai Machine & Tool Co Ltd
TWSE:4526
|
TW |
|
Jewett-Cameron Trading Company Ltd
NASDAQ:JCTCF
|
US |
|
M
|
MEP Infrastructure Developers Ltd
NSE:MEP
|
IN |
|
Achilles Corp
TSE:5142
|
JP |
|
Consolidated Water Co Ltd
NASDAQ:CWCO
|
KY |
|
I
|
Israel Acquisitions Corp
NASDAQ:ISRL
|
US |
|
Patriot Battery Metals Inc
XTSX:PMET
|
CA |
|
Grupo Pochteca SAB de CV
BMV:POCHTECB
|
MX |
|
B
|
Biomind Labs Inc
NEO:BMND
|
CA |
ATAI Life Sciences NV
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company engages in the treatment of mental health disorders. The company is headquartered in Berlin, Berlin and currently employs 81 full-time employees. The company went IPO on 2021-06-18. The firm is aiming to transform the treatment of mental health disorders.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company engages in the treatment of mental health disorders. The company is headquartered in Berlin, Berlin and currently employs 81 full-time employees. The company went IPO on 2021-06-18. The firm is aiming to transform the treatment of mental health disorders.
Cash Position: Atai ended Q3 with $304 million in cash and access to a $175 million debt facility, giving the company a runway into 2025.
Pipeline Progress: The company reported initial positive Phase 1 results for GRX-917 and KUR-101 and completed enrollment for a key Phase 2a trial of PCN-101 (R-ketamine) for treatment-resistant depression.
Upcoming Catalyst: Top-line results from the Phase 2a PCN-101 trial are expected around the end of this year, which management views as a potentially significant value inflection point.
Focus on At-Home Use: PCN-101 aims for unsupervised at-home administration, rapid onset, and intermittent dosing, targeting a safety profile comparable to placebo on key side effects.
RL007 Program: Phase 2a for RL007 in CIAS will use FDA-supported endpoints, with doses chosen based on earlier positive biomarker data. The larger Phase 2b is expected to start this year.
Strategic Vision: Management highlighted the importance of combining drug development with digital therapeutics to drive durable behavioral change in mental health.
